[Sinovac to Host Conference Call to Report First Quarter 2015 Unaudited Financial Results BEIJING, May 7, 2015 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the first quarter, ended March 31, 2015, before market opens on Friday, May 15, 2015. The Company will] []
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
[Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results - Conference call scheduled for April 20, 2015 at 8:00 a.m. ET - BEIJING, April 20, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2014. Fourth] []
[Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results - Conference call scheduled for April 20, 2015 at 8:00 a.m. ET - BEIJING, April 20, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2014. Fourth] []
[Sinovac Files 2014 Annual Report on Form 20-F The Company will provide a hard copy of its complete audited financial statements to its shareholders upon request, free of charge. Requests for a hard copy of the 2014 Annual Report can be made through the Contact IR page in the Investor Relations section of the Company's website by submitting complete mailing] []
[Sinovac Files 2014 Annual Report on Form 20-F The Company will provide a hard copy of its complete audited financial statements to its shareholders upon request, free of charge. Requests for a hard copy of the 2014 Annual Report can be made through the Contact IR page in the Investor Relations section of the Company's website by submitting complete mailing] []
[None (Title of Class) Indicate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered by the annual report. 55,809,661 common shares as of December 31, 2014 o Yes x No o Yes x No x Yes o No x Yes o No Large accelerated filer] [List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Tangshan Yian Biological Engineering Co., Ltd., a PRC company 3. Sinovac Biotech Co., Ltd., a PRC company 4. Sinovac Research and Development Co., Ltd. (formerly known as Beijing Sinovac Biological Technology Co., Ltd.), a PRC company 5. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company] [CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION BY THE CHIEF FINANCIAL OFFICER I, Nan Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. April 29 , 2015 Weidong Yin Weidong Yin Chief Executive Officer EX-13.1 5 a14-26055_1ex13d1.htm EX-13.1] [CERTIFICATION BY THE CHIEF FINANCIAL OFFICER (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. April 29 , 2015 Nan Wang Chief Financial Officer EX-13.2 6 a14-26055_1ex13d2.htm EX-13.2] [Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-161827) pertaining to Sinovac Biotech Ltd.s 2003 Stock Option Plan and the Registration Statement on Form S-8 (No. 333-190980) pertaining to Sinovac Biotech Ltd.s 2012 Share Incentive Plan of our reports dated April 29, 2015, with respect to] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-161827) pertaining the Companys 2003 Stock Option Plan and the Registration Statement on Form S-8 (No. 333-190980) pertaining to the Companys 2012 Share Incentive Plan of our report dated April 29, 2013 with respect to the consolidated financial]
[None (Title of Class) Indicate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered by the annual report. 55,809,661 common shares as of December 31, 2014 o Yes x No o Yes x No x Yes o No x Yes o No Large accelerated filer] [List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Tangshan Yian Biological Engineering Co., Ltd., a PRC company 3. Sinovac Biotech Co., Ltd., a PRC company 4. Sinovac Research and Development Co., Ltd. (formerly known as Beijing Sinovac Biological Technology Co., Ltd.), a PRC company 5. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company] [CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION BY THE CHIEF FINANCIAL OFFICER I, Nan Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. April 29 , 2015 Weidong Yin Weidong Yin Chief Executive Officer EX-13.1 5 a14-26055_1ex13d1.htm EX-13.1] [CERTIFICATION BY THE CHIEF FINANCIAL OFFICER (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. April 29 , 2015 Nan Wang Chief Financial Officer EX-13.2 6 a14-26055_1ex13d2.htm EX-13.2] [Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-161827) pertaining to Sinovac Biotech Ltd.s 2003 Stock Option Plan and the Registration Statement on Form S-8 (No. 333-190980) pertaining to Sinovac Biotech Ltd.s 2012 Share Incentive Plan of our reports dated April 29, 2015, with respect to] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-161827) pertaining the Companys 2003 Stock Option Plan and the Registration Statement on Form S-8 (No. 333-190980) pertaining to the Companys 2012 Share Incentive Plan of our report dated April 29, 2013 with respect to the consolidated financial]
[Sinovac Provides Updates on Pipeline Vaccines BEIJING, March 17, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. ), a leading provider of biopharmaceutical products in China, today provided updates on the Company's pipeline vaccines. EV71 vaccine. EV71 is a virus that causes hand, foot and mouth disease (HFMD) and is the primary cause of most severe and fatal cases of hand, foot] [Sinovac to Participate in China Medical and Healthcare Investment Conference Beijing, March 18,2014/PRNewswire/--Sinovac Biotech Ltd.(NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the Company will participate in the China Medical and Healthcare Investment Conference sponsored by T.H capital and Dong Xing Security, to be held at China World Hotel from March 23 to March 25. The] [Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2014 Unaudited Financial Results BEIJING, April 10, 2015 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the fourth quarter and full year, ended December 31, 2014, before market opens on Monday,] []
